Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......


JAMA. 1965;191(5):408. doi:10.1001/jama.1965.03080050054018.
Text Size: A A A
Published online


Pursuit of the etiology of some obscure disorders of the nervous system has led to the discovery of previously unknown systemic diseases, in which the neural disturbance has been the primary or only manifestation of the general illness. Progresssive familial myoclonic epilepsy, described in 1881 by Unverricht, now seems to be one of these conditions.

In 1911, Lafora described amyloid intraneuronal inclusion bodies as the unique pathologic feature of Unverricht's syndrome. Subsequently, other neural alterations were reported in patients with Unverricht's syndrome. Abiotrophy, lipid disturbances, and degenerative processes were evoked as etiologic factors. Then, in 1955, Harriman and Millar1 found material similar to the Lafora bodies in cardiac muscle and hepatic cells and identified the intracellular substance as an acid mucopolysaccharide. They emphasized the unity of this form of Unverricht's syndrome, both clinically and pathologically.

In the February issue of the Archives of Neurology, Schwarz and Yanoff2 describe inclusion bodies


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.